Literature DB >> 19129740

Effects of acetylsalicylic acid on increase of fibrin network porosity and the consequent upregulation of fibrinolysis.

Shu He1, Niklas Bark, Haiyao Wang, Jan Svensson, Margareta Blombäck.   

Abstract

Our earlier study in vivo showed that a lower dose of acetylsalicylic acid (ASA) brought greater enhancement in fibrin gel permeability (Ks) than a higher dose. To assess whether this finding related to modifications of fibrinogen clotting property by ASA, purified fibrinogen was incubated with ASA and/or salicylic acid (SA). The fibrinogen product was examined. Fibrinogen "clotting time" was not affected. Shortening of fibrin clot "lysis time" paralleled the increase of fibrin network porosity demonstrated by measurements of liquid permeability (Ks), fibrin fiber thickness, and 3-dimensional microscopic image, in a low ASA concentration-dependent way. Ks levels were not altered by SA alone but significantly decreased in samples treated by both where the concentrations were low for ASA and high for SA. In conclusion, ASA at the concentrations used did not influence the rate of fibrinogen gelation by thrombin. However, assembly of fibrin monomers was most probably altered, leading to enhancement of fibrin fiber thickness. A looser network was constructed by the thicker fibrin fibers, which benefits fibrinolysis. According to the known mechanism that SA interferes with ASA in preventing acetylation of platelet's proteins, an explanation for the low ASA concentration-dependent effects on fibrin network structure may be that fewer molecules of SA-the hydrolytic product of ASA-are generated from lower doses of ASA, which block acetylation of fibrinogen to a smaller extent and thus more significantly impair fibrin formation.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19129740     DOI: 10.1097/FJC.0b013e3181953e0f

Source DB:  PubMed          Journal:  J Cardiovasc Pharmacol        ISSN: 0160-2446            Impact factor:   3.105


  7 in total

1.  Nanoparticle diffusion measures bulk clot permeability.

Authors:  Richard Chasen Spero; Rachel K Sircar; Ryan Schubert; Russell M Taylor; Alisa S Wolberg; Richard Superfine
Journal:  Biophys J       Date:  2011-08-17       Impact factor: 4.033

Review 2.  Mechanisms of fibrin polymerization and clinical implications.

Authors:  John W Weisel; Rustem I Litvinov
Journal:  Blood       Date:  2013-01-10       Impact factor: 22.113

3.  In vitro studies using a global hemostasis assay to examine the anticoagulation effects in plasma by the direct thrombin inhibitors: dabigatran and argatroban.

Authors:  Shu He; Håkan Wallèn; Niklas Bark; Margareta Blombäck
Journal:  J Thromb Thrombolysis       Date:  2013-02       Impact factor: 2.300

Review 4.  Molecular mechanisms affecting fibrin structure and stability.

Authors:  Susan T Lord
Journal:  Arterioscler Thromb Vasc Biol       Date:  2011-03       Impact factor: 8.311

5.  Effects of Post-Translational Modifications of Fibrinogen on Clot Formation, Clot Structure, and Fibrinolysis: A Systematic Review.

Authors:  Judith J de Vries; Charlotte J M Snoek; Dingeman C Rijken; Moniek P M de Maat
Journal:  Arterioscler Thromb Vasc Biol       Date:  2020-01-09       Impact factor: 8.311

6.  Development of a mesoscopic framework spanning nanoscale protofibril dynamics to macro-scale fibrin clot formation.

Authors:  Naoki Takeishi; Taiki Shigematsu; Ryogo Enosaki; Shunichi Ishida; Satoshi Ii; Shigeo Wada
Journal:  J R Soc Interface       Date:  2021-11-10       Impact factor: 4.118

7.  Fibrin clot structure and platelet aggregation in patients with aspirin treatment failure.

Authors:  Søs Neergaard-Petersen; Ramzi Ajjan; Anne-Mette Hvas; Katharina Hess; Sanne Bøjet Larsen; Steen Dalby Kristensen; Erik Lerkevang Grove
Journal:  PLoS One       Date:  2013-08-19       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.